Abstract
Patients with early-stage HER2-overexpressing breast cancer struggle with treatment resistance in 20%–40% of cases. More information is needed to predict HER2 therapy response and resistance in vivo. In this study, we perform (phospho)proteomics analysis of pre-treatment HER2+ needle biopsies of early-stage invasive breast cancer to identify molecular signatures predictive of
... read more